AU2017327994B2 - Cell death biomarker - Google Patents

Cell death biomarker Download PDF

Info

Publication number
AU2017327994B2
AU2017327994B2 AU2017327994A AU2017327994A AU2017327994B2 AU 2017327994 B2 AU2017327994 B2 AU 2017327994B2 AU 2017327994 A AU2017327994 A AU 2017327994A AU 2017327994 A AU2017327994 A AU 2017327994A AU 2017327994 B2 AU2017327994 B2 AU 2017327994B2
Authority
AU
Australia
Prior art keywords
bap1
protein
cancer
wild
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017327994A
Other languages
English (en)
Other versions
AU2017327994A1 (en
Inventor
Samuel JANES
Krishna KOLLURI
Neelam KUMAR
Ultan Mcdermott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of AU2017327994A1 publication Critical patent/AU2017327994A1/en
Assigned to UCL BUSINESS LTD reassignment UCL BUSINESS LTD Amend patent request/document other than specification (104) Assignors: UCL BUSINESS PLC
Application granted granted Critical
Publication of AU2017327994B2 publication Critical patent/AU2017327994B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017327994A 2016-09-16 2017-09-15 Cell death biomarker Active AU2017327994B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1615842.0A GB201615842D0 (en) 2016-09-16 2016-09-16 Cell death biomarker
GB1615842.0 2016-09-16
PCT/GB2017/052733 WO2018051110A1 (en) 2016-09-16 2017-09-15 Cell death biomarker

Publications (2)

Publication Number Publication Date
AU2017327994A1 AU2017327994A1 (en) 2019-04-04
AU2017327994B2 true AU2017327994B2 (en) 2023-09-14

Family

ID=57288813

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017327994A Active AU2017327994B2 (en) 2016-09-16 2017-09-15 Cell death biomarker

Country Status (8)

Country Link
US (2) US11789012B2 (https=)
EP (1) EP3513192B1 (https=)
JP (1) JP7211936B2 (https=)
AU (1) AU2017327994B2 (https=)
DK (1) DK3513192T3 (https=)
ES (1) ES2863274T3 (https=)
GB (1) GB201615842D0 (https=)
WO (1) WO2018051110A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN112961864A (zh) * 2021-02-26 2021-06-15 广州市妇女儿童医疗中心 突变的asxl3基因及应用
CN114478797B (zh) * 2021-11-24 2023-10-27 中山大学附属第五医院 一种靶向ddx24蛋白的水解靶向嵌合体及其应用
US12456104B2 (en) 2023-02-10 2025-10-28 linch Limited Dynamic multi-path transfers
CN117843657B (zh) * 2023-12-30 2025-08-05 新乡医学院 Brd4/nampt双靶向抑制剂及其作为抗肝癌药物的应用
US12608709B2 (en) 2024-03-15 2026-04-21 Degensoft Ltd. Decentralized systems and methods for response generation to API calls
US12574234B2 (en) 2024-04-18 2026-03-10 Degensoft Ltd Secure cross-chain atomic swaps

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106002A1 (en) * 2011-02-16 2013-07-18 Memorial Sloan-Kettering Cancer Center Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20020169123A1 (en) 2001-02-27 2002-11-14 The Trustees Of The University Of Pennsylvania Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells
NZ574009A (en) * 2006-06-20 2012-01-12 Genentech Inc Methods and materials for observing apoptosis by detecting fragments of clathrin-pathway components
WO2012040614A1 (en) * 2010-09-23 2012-03-29 The Washington University Compositions and methods for detecting cancer metastasis
JP6108571B2 (ja) 2013-03-28 2017-04-05 国立大学法人東北大学 食道癌の発症リスクを判定する方法及びキット
US9868736B2 (en) 2013-10-10 2018-01-16 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
US20160101071A1 (en) * 2014-04-28 2016-04-14 Wisconsin Alumni Research Foundation Combination cancer treatment
CA2948883A1 (en) 2014-06-02 2015-12-10 Pharmakea, Inc. Deubiquitinase inhibitors
SG11201610610YA (en) 2014-06-19 2017-01-27 Sloan Kettering Inst Cancer Biomarkers for response to ezh2 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106002A1 (en) * 2011-02-16 2013-07-18 Memorial Sloan-Kettering Cancer Center Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R POLANSKI ET AL: CELL DEATH AND DISEASE, vol. 6, no. 10, 1 October 2015 (2015-10-01), pages e1893, XP055418422, DOI: 10.1038/cddis.2015.234 *
Sarhan, D, et al. "A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells." Cancer Immunology, Immunotherapy 62.8 (2013): 1359-1368. *

Also Published As

Publication number Publication date
DK3513192T3 (da) 2021-03-29
US20240118266A1 (en) 2024-04-11
AU2017327994A1 (en) 2019-04-04
GB201615842D0 (en) 2016-11-02
JP7211936B2 (ja) 2023-01-24
EP3513192B1 (en) 2020-12-23
US20190257818A1 (en) 2019-08-22
WO2018051110A1 (en) 2018-03-22
JP2020500502A (ja) 2020-01-16
EP3513192A1 (en) 2019-07-24
US11789012B2 (en) 2023-10-17
ES2863274T3 (es) 2021-10-11

Similar Documents

Publication Publication Date Title
AU2017327994B2 (en) Cell death biomarker
US20200206344A1 (en) Methods for modulating the interaction between ews-fli1 and baf complexes
WO2020081556A2 (en) Non-canonical swi/snf complex and uses thereof
CA2517416A1 (en) Therapeutic compositions
WO2017079558A1 (en) TARGETING CASEIN KINASE-1 AND PI3K/AKT/mTOR PATHWAYS FOR TREATMENT OF C-MYC-OVEREXPRESSING CANCERS, ORGAN TRANSPLANT ASSOCIATED COMPLICATIONS AND AUTOIMMUNE DISEASES
US20240398804A1 (en) Methods of treating cancer having an active wnt/beta-catenin pathway
EP3976778A2 (en) Treatment of alt cancers
CN114042160B (zh) Ctd-2256p15.2及其编码微肽作为靶点在开发肿瘤治疗药物中的应用
US20170157212A1 (en) Cdk modulators and methods for the treatment of cancer
Morales et al. GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion–positive rhabdomyosarcoma
US20240156800A1 (en) Ep300 degrader and uses thereof in neuroblastoma
US7160681B2 (en) Method for regulating cell growth and assays related thereto
US20230042367A1 (en) Methods and compositions for treating cancers having f-box and wd-repeat protein 7 (fbxw7) alterations and/or cyclin l1 (ccnl1) gain or amplification
US20250146080A1 (en) Methods for overcoming tazemetostat-resistance in cancer patients
Zhao et al. Triazole/thiadiazole substituted 4′-demethylepipodophyllotoxin derivatives induced apoptosis in HeLa cells by up-regulating TMEM133
Oldberg Elucidating the Novel Role for Core Binding Factor beta in Osteosarcoma Protein Translation
Masanas Jimenez Prognostic and therapeutic significance of KIF11 in neuroblastoma
Liu Analysis of Pten-Null Primary Mouse Astrocytes Revealed Common Differentially Expressed Genes with Human Glioblastoma Transcriptomes
CN120939242A (zh) 一种拮抗胶质瘤的干扰肽药物及其应用
Gregg BSc (Hons.) Biomedical Science
US20210401931A1 (en) Methods and materials for treating cancer
JP2026501822A (ja) 癌における細胞致死性の誘導
Perl Leveraging Small Molecule Activators of Protein Phosphatase 2A (PP2A) to Elucidate PP2As Role in Regulating DNA Replication and Apoptosis
US20180271857A1 (en) Treatment of cancer by inhibiting ezh2 activity
Li et al. Identification of ZER6 Isoform p52-ZER6 as an Antitumour Therapeutic Response Determinant for MDM2-p53 Binding Inhibitors

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UCL BUSINESS LTD

Free format text: FORMER NAME(S): UCL BUSINESS PLC

FGA Letters patent sealed or granted (standard patent)